ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase and Increased binding to Biglycan.
Artikel i vetenskaplig tidskrift, 2009

Objective- Apolipoprotein CIII (apoCIII) is an independent risk factor for cardiovascular disease, but the molecular mechanisms involved are poorly understood. Here, we investigated potential proatherogenic properties of apoCIII-containing LDL from hypertriglyceridemic patients with type 2 diabetes. Research design and methods - LDL was isolated from controls and subjects with type 2 diabetes, and from apoB transgenic mice. LDL-biglycan binding was analyzed with a solid-phase assay using immunoplates coated with biglycan. Lipid composition was analyzed with mass spectrometry. Hydrolysis of LDL by sphingomyelinase was analyzed after labeling plasma LDL with [(3)H]sphingomyelin. ApoCIII isoforms were quantified after isoelectric focusing. Human aortic endothelial cells were incubated with desialylated apoCIII or with LDL enriched with specific apoCIII isoforms. Results- We showed that enriching LDL with apoCIII only induced a small increase in LDL-proteoglycan binding, and this effect was dependent on a functional Site A in apoB100. Our findings indicated that intrinsic characteristics of the diabetic LDL other than apoCIII per se are responsible for further increased proteoglycan binding of diabetic LDL with high endogenous apoCIII, and we showed alterations in the lipid composition of diabetic LDL with high apoCIII. We also demonstrated that high apoCIII increased susceptibility of LDL to hydrolysis and aggregation by SMase. In addition, we demonstrated that sialylation of apoCIII increased with increasing apoCIII content, and that sialylation of apoCIII was essential for its proinflammatory properties. Conclusions- We have demonstrated a number of features of apoCIII-containing LDL from hypertriglyceridemic patients with type 2 diabetes that could explain the proatherogenic role of apoCIII.

Författare

A Hiukka

Marcus Ståhlman

Göteborgs universitet

Camilla Pettersson

Göteborgs universitet

Malin Levin

Göteborgs universitet

Martin Adiels

Göteborgs universitet

Susann Teneberg

Göteborgs universitet

ES Leinonen

Lillemor Mattsson Hultén

Göteborgs universitet

Olov Wiklund

Göteborgs universitet

M Oresic

Sven-Olof Olofsson

Göteborgs universitet

MR Taskinen

K Ekroos

Jan Borén

Göteborgs universitet

Diabetes

1939-327X (ISSN)

Vol. 58 2018-2026

Ämneskategorier

MEDICIN OCH HÄLSOVETENSKAP

DOI

10.2337/db09-0206

PubMed

19502413